

Renalytix plc
("Renalytix" or the "Company")

Total Voting Rights

LONDON and NEW YORK, 30 August 2024 - [Renalytix plc](https://www.renalytix.com) (NASDAQ: RNLX) (LSE: RENX) announces that at today's date, the Company's total issued share capital is 165,925,513 Ordinary Shares of £0.0025 each in the capital of the Company ("Ordinary Shares"). Each Ordinary Share carries the right to one vote at a general meeting of the Company. The Company does not hold any Ordinary Shares in treasury.

The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser and Joint Broker)
Nicholas Moore / Nick Harland / Ben Good

Tel: 020 7710 7600

Oberon Capital (Joint Broker)
Mike Seabrook / Nick Lovering

Tel: 020 3179 5300

Walbrook PR Limited
Paul McManus / Alice Woodings / Charlotte Edgar

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654 / 07884 664 686

CapComm Partners
Peter DeNardo

Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TVRQKCBPNBKDBFB